The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Open accessAbstract
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial effect was driven by a 38% reduction in CV mortality with no significant decrease in nonfatal myocardial infarction or stroke. Empagliflozin also caused a 35% reduction in hospitalization for heart failure without affecting hospitalization for unstable angina. Although sodium–glucose cotransporter 2 inhibitors exert multiple metabolic benefits (decreases in HbA1c, body weight, and blood pressure and an increase in HDL cholesterol), all of which could reduce CVD risk, it is unlikely that the reduction in CV mortality can be explained by empagliflozin’s metabolic effects. More likely, hemodynamic effects, specifically reduced blood pressure and decreased extracellular volume, are responsible for the reduction in CV mortality and heart failure hospitalization. In this Perspective, we will discuss possible mechanisms for these beneficial effects of empagliflozin and their implications for the care of T2DM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Cruickshank, K., Riste, L., Anderson, S. G., Wright, J. S., Dunn, G., & Gosling, R. G. (2002) · Circulation · doi:10.1161/01.cir.0000033824.02722.f7 · Cited by 1,531
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“(24) and empagliflozin (25) cause a ro-”
BackgroundInfluentialPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Roman, M. J., Devereux, R. B., Kizer, J. R., Lee, E. T., Galloway, J. M., Ali, T., Umans, J. G., & Howard, B. V. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089078 · Cited by 1,080
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Self-citationLv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 4×
“Intensive glycemic control failed to decrease CV events in the UK Prospective Diabetes Study (UKPDS) (3), Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (4), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study (5), and Veterans Affairs Diabetes Tri…”
BackgroundMethodInfluentialWilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke · doi:10.1161/01.str.0000257974.06317.49 · Cited by 475
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Self-citationKetone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Self-citationErdmann, E., Dormandy, J. A., Charbonnel, B., Massi-Benedetti, M., Moules, I. K., & Skene, A. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.12.048 · Cited by 378
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
DEFRONZO, R. (1997) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00012-0 · Cited by 277
Self-citationRelationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes
Levelt, E., Mahmod, M., Piechnik, S. K., Ariga, R., Francis, J. M., Rodgers, C. T., Clarke, W. T., Sabharwal, N., Schneider, J. E., Karamitsos, T. D., et al. (2016) · Diabetes · doi:10.2337/db15-0627 · Cited by 254
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00267.2015 · Cited by 165
Self-citationRevisiting the links between glycaemia, diabetes and cardiovascular disease
Sattar, N. (2013) · Diabetologia · doi:10.1007/s00125-012-2817-5 · Cited by 163 · cited 2×
“Consequently, lowering blood pressure and improving lipid profile have a greater effect to reduce CVD risk than lowering plasma glucose concentration in T2DM (12) (Fig.”
BackgroundSulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 157
Odden, M. C., Amadu, A.-R., Smit, E., Lo, L. J., & Peralta, C. A. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.024 · Cited by 154
Cardiovascular Morbidity and Mortality of the Metabolic Syndrome
Obunai, K., Jani, S., & Dangas, G. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.003 · Cited by 134
Heise, T., SEMAN, L. J., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 131
Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T. D., Ito, K., Harada, T., Takahashi, H., Ikegami, M., Anzawa, R., & Yoshimura, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130605 · Cited by 117
Dziuba, J., Alperin, P., Racketa, J., Iloeje, U. H., Goswami, D., Hardy, E., Perlstein, I., Grossman, H. L., & Cohen, M. M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12261 · Cited by 103
Saremi, A., Schwenke, D. C., Buchanan, T. A., Hodis, H. N., Mack, W. J., Banerji, M., Bray, G. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300346 · Cited by 101
Self-citationSinclair, A. J., Bode, B. W., Harris, S. B., Vijapurkar, U., Mayer, C., Fung, A., Shaw, W. C., Usiskin, K., Desai, M. G., & Meininger, G. E. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-37 · Cited by 85
Understanding EMPA-REG OUTCOME
Muskiet, M. H. A., van Raalte, D. H., van Bommel, E. J. M., Smits, M. M., & Tonneijck, L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00424-6 · Cited by 79
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Viscoli, C. M., Kernan, W. N., & Young, L. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605904 · Cited by 50
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects
Rizza, S., Cardellini, M., Porzio, O., Pecchioli, C., Savo, A., Cardolini, I., Senese, N., Lauro, D., Sbraccia, P., Lauro, R., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.12.021 · Cited by 35
Thuesen, L., Christiansen, J. S., Sørensen, K. E., Ørskov, H., & HENNINGSEN, P. (1988) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518809085396 · Cited by 18
Cited by
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citationRenal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Self-citationYe, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S. P., Rodgers, A., Mahaffey, K. W., Cannon, C. P., Perkovic, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014908 · Cited by 247
Metadata
- Authors
- Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-14
- Volume
- 39
- Issue
- 5
- Pages
- 717-725
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2341643234
- Cited by
- 295
- References
- 62
- FWCI
- 47.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.